Cyclophosphamide and Doxorubicin
Induced Melanonychia: A Case Report
Published: January 1, 2017 | DOI: https://doi.org/10.7860/JCDR/2017/23041.9216
Vivek Bhanubhai Prajapati, Sharath Madhyastha, Raviraj Acharya, Vinaya Gopalaswamy, Akhila Doddamani
1. Intern, Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India.
2. Assistant Professor, Department of General Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.
3. Professor, Department of General Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.
4. Senior Resident, Department of General Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.
5. Lady Medical Officer, Department of Community Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.
Correspondence
Dr. Sharath Madhyastha,
Assistant Professor, Department of General Medicine, Kasturba Medical College, Manipal University,
Manipal-576104, Karnataka, India.
E-mail: dr.sharathymc@gmail.com
Chemotherapeutic agents may rarely cause discoloration and hyperpigmentation of the nails. We present a patient who developed blackish discoloration of nails also referred as melanonychia during six cycles of R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) for the treatment of Non Hodgkin Lymphoma (NHL) follicular type. The patient developed blackish brown discoloration in all the nails. As suggested by previous literature evidence the melanonychia could be associated with cyclophosphamide and doxorubicin. According to the Naranjo causality assessment scale, we established that there was a ‘probable’ association of nail discoloration with the drug.
[
FULL TEXT ] | [ PDF]